Cargando…

Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats

BACKGROUND/AIMS: Magnesium (Mg) is an essential element for vascular function and blood pressure regulation. Several studies have demonstrated that Mg concentration is inversely associated with blood pressure, and that Mg supplementation attenuates hypertension. The purpose of this study was to eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Kyubok, Kim, Tae Hee, Kim, Yeong Hoon, Kim, Yang Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604610/ https://www.ncbi.nlm.nih.gov/pubmed/23526071 http://dx.doi.org/10.3904/kjim.2013.28.2.197

Ejemplares similares

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
por: Rudolph, Ulrike Maria, et al.
Publicado: (2020)

Mass spectrometric analysis of TRPM6 and TRPM7 from small intestine of omeprazole-induced hypomagnesemic rats
por: Kampuang, Nattida, et al.
Publicado: (2022)

Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations
por: Kim, Da-Rae, et al.
Publicado: (2013)

Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide
por: Flack, J M
Publicado: (2007)

Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers
por: Ekman, Elisabet, et al.
Publicado: (2010)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats
por: Yoon, Namsik, et al.
Publicado: (2013)

Response surface analyses of antihypertensive effects of angiotensin receptor blockers and amlodipine or hydrochlorothiazide combination therapy in patients with essential hypertension
por: Cho, Minhee, et al.
Publicado: (2023)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Observations of the Effects of Angiotensin II Receptor Blocker on Angiotensin II-Induced Morphological and Mechanical Changes in Renal Tubular Epithelial Cells Using Atomic Force Microscopy
por: Kim, Jin Sug, et al.
Publicado: (2018)

Effects of Angiotensin-II Receptor Blocker on Inhibition of Thrombogenicity in a Canine Atrial Fibrillation Model
por: Choi, Jong-Il, et al.
Publicado: (2016)

Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials
por: Cuspidi, Cesare, et al.
Publicado: (2009)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Weight loss has an additive effect on the proteinuria reduction of angiotensin II receptor blockers in hypertensive patients with chronic kidney disease
por: Ahn, Shin Young, et al.
Publicado: (2018)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
por: Choisy, Stéphanie C., et al.
Publicado: (2015)

Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure
por: YOON, NAMSIK, et al.
Publicado: (2013)

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
por: Choi, Won Joon, et al.
Publicado: (2022)

Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data
por: Hiroi, Shinzo, et al.
Publicado: (2016)

Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation
por: Park, Jeong-Hwan, et al.
Publicado: (2009)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese
por: Gong, Hong-Tao, et al.
Publicado: (2019)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Ku, Elaine, et al.
Publicado: (2018)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
por: Lee, Jin Wook, et al.
Publicado: (2023)

Antihypertensive Effects of Standardized Asafoetida: Effect on Hypertension Induced by Angiotensin II
por: Kazemi, Farzaneh, et al.
Publicado: (2020)

New Users of Angiotensin II Receptor Blocker–Versus Angiotensin‐Converting Enzyme Inhibitor–Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD‐BP and SPRINT
por: King, Jordan B., et al.
Publicado: (2023)

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction
por: Lee, Jang Hoon, et al.
Publicado: (2016)

Effects of a Step-Therapy Program for Angiotensin Receptor Blockers on Antihypertensive Medication Utilization Patterns and Cost of Drug Therapy
por: Yokoyama, Krista, et al.
Publicado: (2007)

Antihypertensive Effects of Artemisia scoparia Waldst in Spontaneously Hypertensive Rats and Identification of Angiotensin I Converting Enzyme Inhibitors
por: Cho, Jeong-Yong, et al.
Publicado: (2015)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_31ra9vnj518fo021sdko012640